Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azer-cel in r/r NHL, B-ALL, and CLL/SLL
NCT03666000Phase 1Recruiting
- Sponsor
- Imugene
- Start
- Mar 2019
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of azercabtagene zapreleucel in non-Hodgkin lymphoma (NHL), B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL) and 1 more (7 arms), sponsored by Imugene. Primary endpoints: Dose-limiting Toxicities at 720 days and Objective Response Rate at 720 days. Started Mar 2019; status: recruiting.
02
Drugs
azercabtagene zapreleucel
03
Conditions
non-Hodgkin lymphoma (NHL)B cell acute lymphoblastic leukemia (B-ALL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03666000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666000.